Table 1. Comparison of clinical data among pT1c33N0M0 NSCLC patients with different lymph nodes.
| Characteristics | Lymph nodes | χ 2 | P | ||
|---|---|---|---|---|---|
| 0–10 (n = 60) | 11∼16 (n = 89) | >16 (n = 106) | |||
| Gender | |||||
| Male | 43 (71.67%) | 63 (70.79%) | 73 (68.87%) | 0.166 | 0.920 |
| Female | 17 (28.33%) | 26 (29.21%) | 33 (31.13%) | ||
| Age (years) | |||||
| ≤60 | 19 (31.67%) | 37 (41.57%) | 29 (27.36%) | 4.497 | 0.106 |
| >60 | 41 (68.33%) | 52 (58.43%) | 77 (72.64%) | ||
| Smoking history | |||||
| Yes | 16 (26.67%) | 33 (37.08%) | 27 (25.47%) | 3.485 | 0.175 |
| No | 44 (73.33%) | 56 (62.92%) | 79 (74.53%) | ||
| Surgical site | |||||
| Right upper lung | 12 (20.00%) | 17 (19.10%) | 23 (21.70%) | 1.795 | 0.987 |
| Right middle lung | 5 (8.33%) | 7 (7.87%) | 10 (9.43%) | ||
| Right lower lung | 9 (15.00%) | 9 (10.11%) | 14 (13.21%) | ||
| Left upper lung | 23 (38.34%) | 37 (41.57%) | 37 (34.91%) | ||
| Left lower lung | 11 (18.33%) | 19 (21.35%) | 22 (20.75%) | ||
| Tumor max diameter | |||||
| ≤3 cm | 41 (68.33%) | 68 (76.40%) | 54 (50.94%) | 14.262 | 0.001 |
| >3 cm | 19 (31.67%) | 21 (23.60%) | 52 (49.06%) | ||
| T stage | |||||
| T1c stage | 43 (71.67%) | 57 (64.04%) | 53 (50.00%) | 9.416 | 0.052 |
| T2 stage | 11 (18.33%) | 25 (28.09%) | 41 (38.68%) | ||
| T3 stage | 6 (10.00%) | 7 (7.87%) | 12 (11.32%) | ||
| Pathological type | |||||
| Adenocarcinoma | 44 (73.33%) | 56 (62.92%) | 54 (50.94%) | 12.116 | 0.017 |
| Squamous cell carcinoma | 14 (23.34%) | 22 (24.72%) | 43 (40.57%) | ||
| Other | 2 (3.33%) | 11 (12.36%) | 9 (8.49%) | ||
| Preoperative comorbidities | |||||
| Yes | 13 (21.67%) | 17 (19.10%) | 22 (20.75%) | 0.160 | 0.923 |
| No | 47 (78.33%) | 72 (80.90%) | 84 (79.25%) | ||